Search
Transcription factor p65
go.drugbank.com/bio_entities/BE0005551TargetHumansEssential for cytokine gene expression in T-cells (PubMed:15790681). The NF-kappa-B homodimeric RELA-RELA complex appears to be involved in invasin-mediated activation of IL-8 expression. … The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity
Synonyms: Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3Serine/threonine-protein kinase Nek1
go.drugbank.com/bio_entities/BE0009496TargetHumansInvolved in DNA damage checkpoint control and for proper DNA damage repair (PubMed:20230784). … Involved in cilium assembly (PubMed:21211617)
Synonyms: Never in mitosis A-related kinase 1Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized
Revefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigationalThe LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD … [A40025] From the LAMA group, revefenacin is the first once-daily nebulized LAMA treatment.[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]
Categories: Drugs for Obstructive Airway DiseasesVilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigationalThe drug is not yet fully approved for this condition.[L45849] … [L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support
Categories: Experimental Unapproved Treatments for COVID-19Clobetasone
go.drugbank.com/drugs/DB13158ApprovedClobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions
Categories: Corticosteroids, Moderately Potent (Group II)Products: U-CLOSONE CREAM, U-CLOSONE OINTMENTQuinine
go.drugbank.com/drugs/DB00468ApprovedInvestigationalQuinine (GLS-1200) was also investigated in clinical trials for its efficacy in preventing SARS-CoV-2 infection (NCT04408183, terminated) and is planned to be evaluated for preventing sinusitis after endoscopic … Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose.
Categories: Analgesics, Non-NarcoticSynonyms: (R)-(−)-quinine, (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanolAV608
go.drugbank.com/drugs/DB05072InvestigationalAV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).
Pergolide
go.drugbank.com/drugs/DB01186ApprovedVet approvedWithdrawnPergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. … While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes.
Categories: Heterocyclic Compounds with 4 or More Rings, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeBamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigationalfor progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns. … [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.[L40179]
Categories: Experimental Unapproved Treatments for COVID-19